SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
Frequently asked questions
What sector does SpyGlass Pharma, Inc. (SGP) operate in?
SpyGlass Pharma, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is SpyGlass Pharma, Inc. (SGP) current stock price?
As of the latest data, SpyGlass Pharma, Inc. stock price is $29.91, with a previous close of $28.48. SpyGlass Pharma, Inc. gained $1.43 in the last trading session, representing a 5.02% increase.
What is SpyGlass Pharma, Inc. (SGP) current market capitalization?
SpyGlass Pharma, Inc. market cap is approximately 1.00 billion.
What is SpyGlass Pharma, Inc. (SGP) Earnings Per Share (EPS)?
The trailing EPS is -$1.72, and the forward EPS is -$2.72.
What is SpyGlass Pharma, Inc. (SGP) EBITDA?
SpyGlass Pharma, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -21.63 million.
Does SpyGlass Pharma, Inc. (SGP) pay dividends?
No. SpyGlass Pharma, Inc. does not pay a dividend.
When is SpyGlass Pharma, Inc. (SGP) next earnings report?
SpyGlass Pharma, Inc. is expected to release its next earnings report on September 30, 2026.
What is SpyGlass Pharma, Inc. (SGP) beta (volatility) score?
SpyGlass Pharma, Inc. has a beta of -0.045, indicating lower volatility than the overall market.
